Lirilumab IPH2102|cas:1000676-41-4|西域试剂

Lirilumab IPH2102,96.80%

产品编号：Bellancom-P99208| CAS NO：1000676-41-4

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99208	￥3100.00	杭州北京（现货）
Bellancom-P99208	￥8050.00	杭州北京（现货）
Bellancom-P99208	￥12900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Lirilumab IPH2102

产品介绍

Lirilumab (IPH2102) 是一种 anti-KIR 单克隆抗体，其具有抗肿瘤活性。Lirilumab 可用于白血病、头颈部鳞状细胞癌 (SCCHN) 的研究。

生物活性

Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.

体外研究

体内研究

Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rag1KO-Tg KIR mice injected with tumor cells
Dosage:	15 mg/kg
Administration:	intravenous injection; 15 mg/kg; once
Result:	Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.

体内研究

Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rag1KO-Tg KIR mice injected with tumor cells
Dosage:	15 mg/kg
Administration:	intravenous injection; 15 mg/kg; once
Result:	Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.